The 8th BenBedPhar Meeting, themed "Thirty years since the discovery of NRF2" took place at NOVA Medical School on October 10th and 11th, 2024.
The event gathered around 80 participants from 15 European countries. In the 34 oral presentations and 21 posters presented, topics related to new therapeutic approaches involving NRF2, new tools, and drug discovery targeting NRF2 were discussed, as well as the role of NRF2 in inflammation, oxidative stress, brain diseases, and metabolism.
NOVA Medical School was represented through the oral presentations by Professor Miguel Seabra and PhD student António Pimpão from Professor Sofia Pereira's group, as well as with several posters from master's and doctoral students.
The event was organized by Sandra Tenreiro, principal investigator at the Denegeration and Ageing Lab at NOVA Medical School and Fernando Antunes from the Faculty of Sciences at the University of Lisbon.
This meeting is part of a COST action - BenBedPhar (Bench to bedside transition for Pharmacological regulation of NRF2 in NDCs) - which involves nearly 400 participants from more than 30 countries worldwide. It aims to accelerate research and the translation to clinical and market solutions targeting NRF2, which is an important cell regulator in diseases such as cancer, Alzheimer's, Parkinson's, and Age-related Macular Degeneration, among others.
COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Through Actions, COST help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers.